Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Sophia Genetics SA (SOPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/13/2025: SOPH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.33
1 Year Target Price $7.33
| 4 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 30.07% | Avg. Invested days 30 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 297.17M USD | Price to earnings Ratio - | 1Y Target Price 7.33 |
Price to earnings Ratio - | 1Y Target Price 7.33 | ||
Volume (30-day avg) 6 | Beta 1.11 | 52 Weeks Range 2.58 - 5.30 | Updated Date 11/14/2025 |
52 Weeks Range 2.58 - 5.30 | Updated Date 11/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.12 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-04 | When - | Estimate -0.23 | Actual -0.3 |
Profitability
Profit Margin -102.29% | Operating Margin (TTM) -91.78% |
Management Effectiveness
Return on Assets (TTM) -25.59% | Return on Equity (TTM) -86.09% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 272826878 | Price to Sales(TTM) 4.05 |
Enterprise Value 272826878 | Price to Sales(TTM) 4.05 | ||
Enterprise Value to Revenue 3.72 | Enterprise Value to EBITDA -0.3 | Shares Outstanding 67847058 | Shares Floating 50977565 |
Shares Outstanding 67847058 | Shares Floating 50977565 | ||
Percent Insiders 6.43 | Percent Institutions 50.08 |
Upturn AI SWOT
Sophia Genetics SA
Company Overview
History and Background
Sophia Genetics SA was founded in 2011 in Switzerland. It focuses on data-driven medicine and developing a universal approach to data sharing to improve patient outcomes.
Core Business Areas
- Data Analytics Platform: The SOPHiA DDM platform analyzes complex genomic and clinical data to help healthcare professionals make better decisions.
- Clinical Genomic Solutions: Development and provision of software for genomic analysis, clinical reporting, and data sharing.
Leadership and Structure
The company has a board of directors overseeing its operations. Jurgi Camblong is a key leader (Founder) as are several other executives responsible for different aspects of the business (commercial, finance, R&D). The company is publicly traded and therefore subject to corporate governance standards.
Top Products and Market Share
Key Offerings
- SOPHiA DDM Platform: This is Sophia Genetics' primary data analytics platform used to analyze genomic data from Next Generation Sequencing (NGS) and radiomics. While specific market share data is variable and difficult to obtain precisely for just this single platform, in the broader precision oncology market it competes with platforms from companies like Illumina and Roche. It has several hundred hospital and lab clients. Competitors include Illumina, Roche, Thermo Fisher Scientific.
- Clinical Genomic Solutions: Software solutions offered by the company for clinical reporting and data sharing. This includes solutions for hereditary cancer, pharmacogenomics and other disease area. The software competes with similar solution from QIAGEN, and other smaller bioinformatics companies. Competitors include QIAGEN.
Market Dynamics
Industry Overview
The industry is characterized by rapid technological advancements in genomic sequencing, increasing adoption of precision medicine, and regulatory hurdles. The precision oncology market is growing due to advancements in genomic sequencing and targeted therapies.
Positioning
Sophia Genetics is positioned as a data-driven medicine company using AI and machine learning to provide clinical insights. Their competitive advantage lies in their data analytics platform and data sharing network. They are growing in the market, but the competition is fierce.
Total Addressable Market (TAM)
The precision medicine market is expected to reach USD 141.7 billion by 2032. Sophia Genetics is positioned to capture a portion of this expanding TAM through their data analytics platform.
Upturn SWOT Analysis
Strengths
- Data analytics platform
- AI-driven insights
- Data sharing network
- Established partnerships
Weaknesses
- Limited profitability
- Competition from larger players
- Reliance on data quality
- Cash Burn
Opportunities
- Expansion into new disease areas
- Partnerships with pharmaceutical companies
- Increased adoption of precision medicine
- Geographic expansion
Threats
- Regulatory changes
- Data privacy concerns
- Competition from established players
- Economic downturn
Competitors and Market Share
Key Competitors
- ILMN
- ROCHE.SW
- QGEN
Competitive Landscape
Sophia Genetics is competing against much larger companies. It has a focus on software and AI where it attempts to gain an advantage. However, it is still a small player compared to the biggest in the field.
Growth Trajectory and Initiatives
Historical Growth: See public filings for historical information.
Future Projections: See analyst reports for future growth.
Recent Initiatives: See recent company press releases and publications.
Summary
Sophia Genetics is a smaller player in the precision medicine market leveraging AI for data analysis. It is growing, but profitability remains a challenge. It faces intense competition from larger, more established players, requiring strategic partnerships and efficient resource allocation to capitalize on emerging opportunities within the expanding precision medicine landscape and manage data privacy challenges.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- Public filings
- Analyst reports
- Industry reports
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Market share estimates are based on available information and may not be precise. Financial data is based on past performance and is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sophia Genetics SA
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-07-23 | Co-Founder, CEO & Director Dr. Jurgi Camblong M.B.A., Ph.D. | ||
Sector Healthcare | Industry Health Information Services | Full time employees 423 | Website https://www.sophiagenetics.com |
Full time employees 423 | Website https://www.sophiagenetics.com | ||
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is based in Rolle, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.